Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.
about
Insulin-like growth factors promote vasculogenesis in embryonic stem cells{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligaseIdentification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptorModulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectivesInsulin-like growth factor system in cancer: novel targeted therapiesMolecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP)Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KPicropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanismInhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma.Role of ubiquitination in IGF-1 receptor signaling and degradation.Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.Role of receptor tyrosine kinases and their ligands in glioblastoma.Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cellsInhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachInsulin growth factor signaling mediates neuron-like differentiation of adipose-tissue-derived stem cellsPicropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cellsSomething old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationDual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.Insulin-like growth factor-I gene delivery to astrocytes reduces their inflammatory response to lipopolysaccharideThe association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.IGF-1R signaling is essential for the proliferation of cultured mouse spermatogonial stem cells by promoting the G2/M progression of the cell cycle.Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation.Neurotrophin receptor TrkC is an entry receptor for Trypanosoma cruzi in neural, glial, and epithelial cellsInhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.Repression of Igf1 expression by Ezh2 prevents basal cell differentiation in the developing lungInsulin and Insulin-like Growth Factor 1 (IGF-1) Modulate Cytoplasmic Glucose and Glycogen Levels but Not Glucose Transport across the Membrane in Astrocytes.Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition.The insulin receptor: a new target for cancer therapy.Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signalingInsulin growth factor 1 like receptor (IGF-1R).Role of insulin-like growth factor 1 receptor signalling in cancer.Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.Targeting insulin-like growth factor pathways.Targeting the insulin-like growth factor axis as a cancer therapy.β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.Virtual screening of specific insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National Cancer Institute (NCI) molecular databaseRole of insulin-like growth factor-1R system in colorectal carcinogenesisMultiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications.
P2860
Q21134756-66E5984D-E245-4964-9C40-8A5DCB7B2BC8Q24301549-6D3E4ADA-2FC6-4B56-BFCD-AEE2C7532406Q24306866-D443BAF8-338E-4389-B2E0-86067B2FA429Q26852578-5F34706F-54C4-4560-875D-11B1C1F26C9EQ28081603-ADF40A84-AB5E-47A2-8B52-D91312A84534Q28741971-85922FE3-B188-4DB3-A084-2AD8DCA0CB18Q29614757-AD014896-9F0D-43C9-909C-B3E5EA6A60CCQ30597245-004F9B40-4D48-47DE-AAE3-65195829C91BQ31138811-CD6EBDD7-D2CC-45B9-8D01-2B92542D3434Q31149390-C09FB4FC-72A9-4077-AE26-C32A4275713FQ33280993-A205E200-A797-451C-B184-551CC26E3858Q33798860-75ABC7A5-B054-4CD2-93D2-B1D67FD5802CQ33883849-0DEFCE62-827C-4A35-B1DE-E70989E7B9A0Q33890792-C6BA94B7-88B2-481C-825D-BEC41F10234BQ33911578-6954EAFF-93A7-4548-B599-DC6FBF54B92AQ33925323-60BA3BAB-3628-4B2F-806F-6758B10E796BQ34014001-5E4BD36B-E695-4E8C-8267-53E24F73801DQ34292802-ED9659C5-029C-4A44-B6BA-6BE83DF409E4Q34387886-B3222EB2-5E9F-494C-A0D5-CF7574DF1DAAQ34442002-6D911BF5-7E64-43D4-B8A7-68B0878B765FQ34668541-74F4BBDE-34E5-4416-A442-4E58787D03A5Q35030616-AE5B5520-718E-494D-908E-ABACF5CCDDE9Q35036607-4316E77A-FB65-465A-8015-FC08139E485FQ35232280-A16C7454-764B-4D06-9430-DFF6A299A5F1Q35273283-BFDC8955-1275-4777-8F4D-0F80874EF336Q35285518-7180BF39-60F0-40A6-B7F3-9342552F5AE2Q35355964-3208B3E9-1C87-4486-AD83-D9A704C32C30Q35536348-9E171079-3495-4D57-B20D-34D10B1991C6Q35935205-5369D9FD-77A7-4AAC-8120-19DC541FEAECQ35972002-2A2E9FDA-6D11-43C4-852D-A88E69C1215AQ36023735-02AD21E9-7FA6-463A-9A39-E584D781DF67Q36157136-4291D1A2-20E2-445C-B30E-4964A6C944EAQ36163571-EFB428B8-2589-48AE-B608-8F12FCE0DE5CQ36185627-97247069-49CA-465B-A546-0662F69679B5Q36383365-00CA2DCA-B6C7-4377-A566-01A064ADEC9EQ36429684-0FE1C333-A9F8-462A-9B0D-E7F934A720A6Q36483910-B6191142-35CE-4DA6-87D6-7EB822421BABQ36538579-1D65A754-4BD7-47BB-B8AE-BA24066183DAQ36642456-ED958FAF-AB42-4D9C-A530-FE173D83AB96Q36645661-6B93CDBA-A277-413F-824B-A1FBE4932763
P2860
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Cyclolignans as inhibitors of ...... tor and malignant cell growth.
@en
Cyclolignans as inhibitors of ...... tor and malignant cell growth.
@nl
type
label
Cyclolignans as inhibitors of ...... tor and malignant cell growth.
@en
Cyclolignans as inhibitors of ...... tor and malignant cell growth.
@nl
prefLabel
Cyclolignans as inhibitors of ...... tor and malignant cell growth.
@en
Cyclolignans as inhibitors of ...... tor and malignant cell growth.
@nl
P2093
P1433
P1476
Cyclolignans as inhibitors of ...... ptor and malignant cell growth
@en
P2093
Ada Girnita
Fabrizio del Prete
Leonard Girnita
Magnus Axelson
Olle Larsson
P304
P356
10.1158/0008-5472.CAN-03-2522
P407
P577
2004-01-01T00:00:00Z